180 related articles for article (PubMed ID: 32436768)
1. Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs.
Liu L; Li X; Huang C; Bian Y; Liu X; Cao J; Qu W; Miao L
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):527-537. PubMed ID: 32436768
[TBL] [Abstract][Full Text] [Related]
2. The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury.
Wen Y; Zhang G; Wu X
Toxicology; 2022 Jun; 476():153256. PubMed ID: 35835356
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
[TBL] [Abstract][Full Text] [Related]
4. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L
Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961
[TBL] [Abstract][Full Text] [Related]
5. Deleterious effects of 28-day oral co-administration of first-line anti-TB drugs on spleen, blood and bone marrow chromosomes in normal rat.
Sharma R; Sharma VL
Drug Chem Toxicol; 2017 Apr; 40(2):154-163. PubMed ID: 27250504
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
[TBL] [Abstract][Full Text] [Related]
7. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.
Shih TY; Ho SC; Hsiong CH; Huang TY; Hu OY
Curr Drug Metab; 2013 Jul; 14(6):720-8. PubMed ID: 23701163
[TBL] [Abstract][Full Text] [Related]
8. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
9. Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination.
Tasduq SA; Singh K; Satti NK; Gupta DK; Suri KA; Johri RK
Hum Exp Toxicol; 2006 Mar; 25(3):111-8. PubMed ID: 16634329
[TBL] [Abstract][Full Text] [Related]
10. Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport.
Guo HL; Hassan HM; Zhang Y; Dong SZ; Ding PP; Wang T; Sun LX; Zhang LY; Jiang ZZ
Toxicol Sci; 2016 Aug; 152(2):417-28. PubMed ID: 27255380
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics.
Elmorsy E; Attalla SM; Fikry E; Kocon A; Turner R; Christie D; Warren A; Nwidu LL; Carter WG
Hum Exp Toxicol; 2017 Jun; 36(6):616-625. PubMed ID: 27461009
[TBL] [Abstract][Full Text] [Related]
12. CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.
Cheng J; Krausz KW; Li F; Ma X; Gonzalez FJ
Toxicol Appl Pharmacol; 2013 Jan; 266(2):245-53. PubMed ID: 23142471
[TBL] [Abstract][Full Text] [Related]
13. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxal isonicotinoyl hydrazone inhibition of FXR is involved in the pathogenesis of isoniazid-induced liver injury.
Zhang G; Chen L; Wen Y; Rao Z; Wei Y; Wu X
Toxicol Appl Pharmacol; 2020 Sep; 402():115134. PubMed ID: 32673658
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.
Tasduq SA; Kaisar P; Gupta DK; Kapahi BK; Maheshwari HS; Jyotsna S; Johri RK
Phytother Res; 2005 Mar; 19(3):193-7. PubMed ID: 15934014
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Wang Y; Xiang X; Wu SQ; Chen G; Zhang MM; Wang MG; Wang FJ; Sandford AJ; He JQ
Infect Genet Evol; 2017 Jul; 51():198-202. PubMed ID: 28389387
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
19. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
[TBL] [Abstract][Full Text] [Related]
20. An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.
Goh ZH; Tee JK; Ho HK
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
